KPV
Alpha-MSH-derived tripeptide (Lys-Pro-Val) with anti-inflammatory and GI protective properties. Primarily used in physician practice blends with recovery peptides. Very limited standalone human data — no established standalone dose.
KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment of alpha-MSH (alpha-melanocyte stimulating hormone). It is the smallest biologically active fragment of alpha-MSH and retains the anti-inflammatory properties of the parent peptide.
The primary mechanism involves inhibition of NF-κB — a key transcription factor mediating inflammatory signaling — reducing production of pro-inflammatory cytokines including IL-6, IL-8, and TNF-alpha. KPV also interacts with melanocortin receptors which contributes to its anti-inflammatory profile. GI mucosal protective effects have been demonstrated in preclinical colitis models.
KPV is most commonly used in physician practice as a component of blended peptide preparations rather than as a standalone compound. It is frequently combined with BPC-157, TB-500, and GHK in recovery and anti-inflammatory protocols. No established standalone human dose exists.
What are you researching?
Tell us your focus area and we’ll send a personalized research guide.
KPV has essentially no standalone human safety data. The short tripeptide structure suggests low immunogenicity risk but this has not been established. Research use only. Not WADA-prohibited. All information for educational reference only.